| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers H > Headlines for Helix BioPharma Corp. > News item |
Helix BioPharma research indicates L-DOS47 may have potential against lung cancer
New York, June 26 - Helix BioPharma Corp. presented findings suggesting that its L-DOS47 molecule may have potential for treating lung cancer.
In a poster at the Annual Congress on Recombinant Antibodies Conference in Zurich, Helix displayed results showing that L-DOS47 has the ability to target and kill lung tumor cells in vitro and in tumor-bearing mice, as well as the ability to enhance the effect of weakly basic chemotherapeutics.
L-DOS47 is the first immuno-conjugate therapeutic candidate derived from Helix's novel anti-cancer DOS47 platform technology.
Helix is an Aurora, Ont.-based biopharmaceutical company specializing in cancer therapy.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.